Combination of Atezolizumab and Pirfenidone in Second-line and Beyond NSCLC
Conditions: NSCLC Stage IV; NSCLC, Recurrent Intervention: Drug: Atezolizumab Sponsors: University of Kansas Medical Center; parkview cancer institute Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials